---
title: "Sagimet Biosciences Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | SGMT Stock News"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296145941.md"
description: "Sagimet Biosciences (Nasdaq: SGMT) announced an inducement grant of 260,700 stock options to three newly hired employees under Nasdaq Listing Rule 5635(c)(4). The options, granted on August 17, 2026, have a ten-year term and vest over four years. This grant serves as material inducement for employment acceptance."
datetime: "2026-08-17T12:28:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296145941.md)
  - [en](https://longbridge.com/en/news/296145941.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296145941.md)
generator: "portal-rs"
---

# Sagimet Biosciences Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | SGMT Stock News

See more from StockTitan in Google Search and AI answers.Adds StockTitan as a preferred source · opens Google

Add on Google

FOSTER CITY, Calif., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that, in connection with the hiring of 3 employees, the Compensation Committee of Sagimet’s Board of Directors approved that an inducement grant of 260,700 stock options in aggregate to purchase shares of the Company’s Series A common stock be granted on August 17, 2026 to the newly hired employees.

The option awards were granted pursuant to the Nasdaq Rule 5635(c)(4) inducement grant exception as a component of each individual’s employment compensation and were granted as an inducement material to the acceptance of employment with Sagimet.

The options have an exercise price equal to the closing price of Sagimet’s Series A common stock as reported by the Nasdaq Global Market on August 17, 2026. The options have a ten-year term and vest over four years, with 25% of the number of shares underlying each stock option vesting on the one-year anniversary of the applicable vesting commencement date (based on the employee’s employment commencement date) and the remaining shares vesting monthly over 36 months thereafter, subject to each individual’s continued service with Sagimet through the applicable vesting dates.

**About Sagimet Biosciences**

Sagimet is a clinical-stage biopharmaceutical company developing novel FASN inhibitors designed to target dysfunctional metabolic and fibrotic pathways in conditions resulting from the overproduction of the fatty acid, palmitate. FASN is a regulator of lipid synthesis, and a key pathway implicated in multiple diseases, such as acne, MASH and certain FASN-dependent tumor types. For additional information about Sagimet, please visit www.sagimet.com.

**Investor Contact:**  
Joyce Allaire  
LifeSci Advisors  
JAllaire@LifeSciAdvisors.com

**Media Contact:**  
Maggie Whitney  
LifeSci Communications  
mwhitney@lifescicomms.com

### Related Stocks

- [SGMT.US](https://longbridge.com/en/quote/SGMT.US.md)

## Related News & Research

- [Sagimet Biosciences grants 260,700 inducement stock options to new hires](https://longbridge.com/en/news/296143081.md)
- [Sagimet Biosciences Eyes U.S. Phase III Acne Study After Positive China Data](https://longbridge.com/en/news/296073364.md)
- [Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | ZVRA Stock News](https://longbridge.com/en/news/296652469.md)
- [Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) | IOVA Stock News](https://longbridge.com/en/news/296654527.md)
- [Xiao-I Corporation Announces Receipt of Nasdaq Listing Deficiency Notice | AIXI Stock News](https://longbridge.com/en/news/296498514.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**